公开(公告)号：US20170283488A1

公开(公告)日：2017-10-05

申请号：US15473267

申请日：2017-03-29

申请人： OBI Pharma, Inc.

发明人： Cheng-Der Tony YU ,  Jiann-Shiun LAI ,  I-Ju CHEN ,  Chiu-Chun LIN

IPC分类号： C07K16/18 ,  A61K49/00 ,  G01N33/574 ,  G01N33/92 ,  C12N5/16 ,  A61K39/395

CPC分类号： C07K16/18 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/44 ,  G01N33/57438 ,  G01N33/92 ,  G01N2400/00 ,  G01N2405/10

摘要： Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

公开(公告)号：US20180339061A1

公开(公告)日：2018-11-29

申请号：US15996192

申请日：2018-06-01

申请人： OBI Pharma, Inc.

发明人： Cheng-Der Tony YU ,  Jiann-Shiun LAI ,  I-Ju CHEN ,  Chiu-Chun LIN

IPC分类号： A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/4025

摘要： Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

公开(公告)号：US20210228732A1

公开(公告)日：2021-07-29

申请号：US17160282

申请日：2021-01-27

申请人： OBI Pharma, Inc.

发明人： Cheng-Der Tony YU ,  Jiann-Shiun LAI ,  I-Ju CHEN ,  Chiu-Chun LIN

IPC分类号： A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K31/4025 ,  A61K39/395 ,  C07K16/18 ,  C07K16/30

摘要： Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnositcs. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.